Dao P et al. [21] pointed out in their report that intrinsic acquired drug resistance is the key factor for the clinical efficacy of a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is a class of potential anti-cancer drugs and is currently in the clinical research phase. The gene discussed is TNFSF10; the disease is cancer.